<DOC>
	<DOCNO>NCT00459134</DOCNO>
	<brief_summary>RATIONALE : L-arginine supplement may improve quality life sexual function woman cancer survivor . PURPOSE : This randomized clinical trial study L-arginine supplement see well work compare placebo treat woman cancer survivor .</brief_summary>
	<brief_title>L-Arginine Supplements Treating Women Who Are Cancer Survivors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether L-arginine-based nutritional supplement ( ArginMax® ) improve quality life sexual function female cancer survivor . Secondary - Compare quality life patient treat ArginMax® v placebo . - Compare toxicity regimens patient . - Describe sexual function symptom cluster ( ) patient . OUTLINE : This randomize , double-blind , parallel-group , placebo-controlled , multicenter study . Patients stratify accord ECOG performance status ( 0 1 v 2 3 ) , type malignancy ( pelvic v nonpelvic ) , ovarian functional status ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral L-arginine-based nutritional supplement ( ArginMax® ) twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue 12 week absence unacceptable toxicity . Sexual function , quality life , toxicity assess baseline every 4 week 12 week . PROJECTED ACCRUAL : A total 186 patient accrue study .</detailed_description>
	<criteria>INCLUSION CRITERIA : Any female cancer survivor identifies concern sexual quality life answer yes three screen question . Must express interest sexual activity At least 6 month follow completion cancer therapy . Hormonal therapy treatment Herceptin allow . No evidence active cancer base physical exam and/or radiographic image obtain within 3 month study . Absence mental , medical physical disorder know affect sexual function . No participation another study investigational study drug device 30 day prior start study drug . Lab value must meet follow criterion study entry : WBC ≥ 2000 , Hgb ≥ 10gm/dl , creatinine ≤ 1.5 x ULN , plt ≥ 100,000 , T Bili ≤ 1.5 ECOG performance status must 02 . Must able take oral medication Must 18 year old old Must minority ( nonwhite ) female . EXCLUSION CRITERIA : History allergic reaction attribute compound similar chemical biologic composition ArginMax . Currently take blood thinner aspirin ( one 81mg aspirin , one baby aspirin per day allow ) , Persantine , Heparin , Lovenox , Coumadin ( low dose Coumadin catheter patency allow ) . Patients currently take Ginkgo Biloba allow study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac , arrhythmia , psychiatric illness/social situation would limit compliance study requirement and/or ability sexual function . Pregnant woman exclude study ArginMax may agent potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother ArginMax , breastfeed discontinue mother treated ArginMax . Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction ArginMax . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Any plan surgery study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>sexuality reproductive issue</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>